Investigational Drug Information for Mizoribine
✉ Email this page to a colleague
What is the drug development status for Mizoribine?
Mizoribine is an investigational drug.
There have been 5 clinical trials for Mizoribine.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2022.
The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Syndrome. The leading clinical trial sponsors are Asahi Kasei Pharma Corporation, Regeneron Pharmaceuticals, and Sanofi.
There are six hundred and eighteen US patents protecting this investigational drug and twelve international patents.
Summary for Mizoribine
| US Patents | 618 |
| International Patents | 12,852 |
| US Patent Applications | 6,441 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 1,199 |
| Clinical Trial Progress | Phase 3 (2022-05-01) |
| Vendors | 87 |
Recent Clinical Trials for Mizoribine
| Title | Sponsor | Phase |
|---|---|---|
| An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients | Lee's Pharmaceutical Limited | Phase 4 |
| A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) | Regeneron Pharmaceuticals | Phase 3 |
| A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) | Sanofi | Phase 3 |
Clinical Trial Summary for Mizoribine
Top disease conditions for Mizoribine
Top clinical trial sponsors for Mizoribine
US Patents for Mizoribine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Mizoribine | ⤷ Try a Trial | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | Dana-Farber Cancer Institute, Inc. (Boston, MA) | ⤷ Try a Trial |
| Mizoribine | ⤷ Try a Trial | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | ⤷ Try a Trial |
| Mizoribine | ⤷ Try a Trial | Compounds useful for the treatment of metabolic disorders and synthesis of the same | North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC) | ⤷ Try a Trial |
| Mizoribine | ⤷ Try a Trial | Cellulose micropowder | ASAHI KASEI KABUSHIKI KAISHA (Tokyo, JP) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Mizoribine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Mizoribine | Australia | AU2011210567 | 2030-01-29 | ⤷ Try a Trial |
| Mizoribine | Canada | CA2787784 | 2030-01-29 | ⤷ Try a Trial |
| Mizoribine | European Patent Office | EP2528893 | 2030-01-29 | ⤷ Try a Trial |
| Mizoribine | European Patent Office | EP3138838 | 2030-01-29 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
